xPlus Delays Convertible Bond Option Designation Payment Receipt to Nov. 30
Valid market news retained in the public archive without immediate LiveCast distribution.
Related stories
Viatris Commences Tender Offer to Acquire Pacira BioSciences
M impact | EQUITY | Oct 30, 2026, 01:03 PM UTC
Alphabet Shares Fall 12.6%, Erasing About $482 Billion in Market Value
Alphabet shares fell 12.6% Thursday, their steepest one-day decline since the company’s 2004 public debut. The selloff erased about $482 billion in market value as investors focuse
H impact | EQUITY | Oct 30, 2026, 01:01 PM UTC
LyondellBasell Reports Higher Third-Quarter Revenue, Warns Middle East Recovery Will Be Slow
LyondellBasell reported higher quarterly revenue and said Middle East conditions will likely remain fluid. The body is truncated before details on a potential return to pre-conflic
M impact | EQUITY | Oct 30, 2026, 12:59 PM UTC
JPMorgan Downgrades Coursera to Neutral, Cuts Target to $5
JPMorgan lowered its price target from $8 to $5. The new target implies 7.3% upside from Coursera’s Oct. 29 close of $4.66.
M impact | EQUITY | Oct 30, 2026, 12:56 PM UTC
BofA Downgrades Intel to Neutral, Cuts Price Target to $100
BofA lowered its rating on Intel from Buy to Neutral and reduced its price target from $145 to $100.
M impact | EQUITY | Oct 30, 2026, 12:33 PM UTC
Regeneron Shares Rise More Than 8% Premarket After Q3 Earnings Beat
Regeneron reported stronger-than-expected third-quarter earnings, supported by demand for its eye treatments and higher collaboration revenue from Sanofi. Shares gained more than 8
M impact | EQUITY | Oct 30, 2026, 12:31 PM UTC